FDA ap­proves GSK's JAK in­hibitor for rare blood can­cer af­ter three-month de­lay

The FDA ap­proved a new JAK in­hibitor, mo­melo­tinib, from GSK for adults with the rare bone mar­row can­cer myelofi­bro­sis who al­so have ane­mia. The ap­proval marks a ma­jor turn­around for the drug, which had failed ear­li­er stud­ies and was dumped by Gilead for a mere $3 mil­lion in 2018.

Mo­melo­tinib will be mar­ket­ed as Oj­jaara and the whole­sale ac­qui­si­tion cost for a 30-tablet bot­tle will be $26,900, GSK an­nounced Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER